Floatz logo

Tyk-01054

Solid Tumor Malignancies

TYK Medicines, IncPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

27 Active assets in the Solid Tumor Malignancies cohort.

Asset / SponsorPhaseRating
Olutasidenib
Rigel Pharmaceuticals
Phase 4B
Cyclophosphamide
University of Kansas Medical Center
Phase 3B
Pembrolizumab
University of Kansas Medical Center
Phase 3B
Epirubicin
University of Kansas Medical Center
Phase 3B
Nivolumab
University of Kansas Medical Center
Phase 3CCC

View all 35 →

Same molecule, other indications

Tyk-01054 is also rated in:

malignant mesotheliomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →